CY1124943T1 - Φαρμακευτικες συνθεσεις που περιλαμβανουν rpl554 σε hfa-134a για χορηγηση με εισπνοη - Google Patents

Φαρμακευτικες συνθεσεις που περιλαμβανουν rpl554 σε hfa-134a για χορηγηση με εισπνοη

Info

Publication number
CY1124943T1
CY1124943T1 CY20221100086T CY221100086T CY1124943T1 CY 1124943 T1 CY1124943 T1 CY 1124943T1 CY 20221100086 T CY20221100086 T CY 20221100086T CY 221100086 T CY221100086 T CY 221100086T CY 1124943 T1 CY1124943 T1 CY 1124943T1
Authority
CY
Cyprus
Prior art keywords
rpl554
hfa
pharmaceutical compositions
inhalation administration
pharmaceutical composition
Prior art date
Application number
CY20221100086T
Other languages
English (en)
Inventor
Peter Lionel Spargo
Phillip A HAYWOOD
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of CY1124943T1 publication Critical patent/CY1124943T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Abstract

Η παρούσα εφεύρεση αφορά μια υγρή φαρμακευτική σύνθεση η οποία είναι κατάλληλη για χορήγηση με εισπνοή και περιλαμβάνει (i) ένα εναιώρημα σωματιδίων που περιλαμβάνει 9,10-διμεθοξυ-2-(2,4,6-τριμεθυλφαινυλιμινο)-3-(Ν-καρβαμοϋλ-2-αμινοαιθυλ)-3,4,6,7-τετραϋδρο-2Η- πυριμιδο[6,1-a]ισοκινολιν-4-όνη (RPL554)? και (ii) ένα αραιωτικό που είναι 1,1,1,2-τετραφθοροαιθάνιο (HFA-134a), όπου η υγρή φαρμακευτική σύνθεση δεν περιέχει επιφανειοδραστική ουσία. Η εφεύρεση επίσης αφορά μια συσκευή εισπνοής μετρημένης δόσης η οποία περιλαμβάνει την υγρή φαρμακευτική σύνθεση.
CY20221100086T 2018-10-09 2022-02-02 Φαρμακευτικες συνθεσεις που περιλαμβανουν rpl554 σε hfa-134a για χορηγηση με εισπνοη CY1124943T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (1)

Publication Number Publication Date
CY1124943T1 true CY1124943T1 (el) 2023-01-05

Family

ID=64394831

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100086T CY1124943T1 (el) 2018-10-09 2022-02-02 Φαρμακευτικες συνθεσεις που περιλαμβανουν rpl554 σε hfa-134a για χορηγηση με εισπνοη

Country Status (25)

Country Link
US (1) US20210379053A1 (el)
EP (2) EP3960157A1 (el)
JP (1) JP2022513566A (el)
KR (1) KR20210073532A (el)
CN (1) CN112912064A (el)
AU (1) AU2019358585A1 (el)
BR (1) BR112021006712A2 (el)
CA (1) CA3113167A1 (el)
CY (1) CY1124943T1 (el)
DK (1) DK3820446T3 (el)
ES (1) ES2899744T3 (el)
GB (1) GB2578093B (el)
HR (1) HRP20220053T1 (el)
HU (1) HUE057780T2 (el)
IL (1) IL282032A (el)
LT (1) LT3820446T (el)
MX (1) MX2021003599A (el)
PH (1) PH12021550767A1 (el)
PL (1) PL3820446T3 (el)
PT (1) PT3820446T (el)
RS (1) RS62775B1 (el)
SG (1) SG11202102567UA (el)
SI (1) SI3820446T1 (el)
WO (1) WO2020074894A1 (el)
ZA (1) ZA202102039B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048020T2 (hu) 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368413C (en) 1999-03-31 2008-07-29 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
HUE048020T2 (hu) * 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
CN111249260B (zh) * 2014-09-15 2023-01-10 维罗纳制药公司 包含rpl554的液体吸入制剂
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
GB2578093A (en) 2020-04-22
RS62775B1 (sr) 2022-01-31
ZA202102039B (en) 2022-08-31
GB2578093B (en) 2020-11-18
SG11202102567UA (en) 2021-04-29
EP3960157A1 (en) 2022-03-02
ES2899744T3 (es) 2022-03-14
DK3820446T3 (da) 2021-12-06
PL3820446T3 (pl) 2022-03-14
AU2019358585A1 (en) 2021-04-15
EP3820446B1 (en) 2021-11-03
CN112912064A (zh) 2021-06-04
SI3820446T1 (sl) 2022-01-31
BR112021006712A2 (pt) 2021-07-27
GB201816447D0 (en) 2018-11-28
HUE057780T2 (hu) 2022-06-28
JP2022513566A (ja) 2022-02-09
HRP20220053T1 (hr) 2022-04-15
IL282032A (en) 2021-05-31
WO2020074894A1 (en) 2020-04-16
EP3820446A1 (en) 2021-05-19
PT3820446T (pt) 2021-12-03
PH12021550767A1 (en) 2021-10-04
KR20210073532A (ko) 2021-06-18
CA3113167A1 (en) 2020-04-16
MX2021003599A (es) 2021-05-28
US20210379053A1 (en) 2021-12-09
LT3820446T (lt) 2021-12-10

Similar Documents

Publication Publication Date Title
CY1124943T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν rpl554 σε hfa-134a για χορηγηση με εισπνοη
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
MX2018013002A (es) Moduladores de la proteina reguladora de la conductancia transmembrana de la fibrosis quistica.
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
PH12018500088A1 (en) Substituted tricyclics and method of use
CY1121698T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
CL2018000911A1 (es) Pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas y método de uso
BR112019004420A2 (pt) derivado de pirimidina do vírus anti-influenza
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
EA201990820A1 (ru) Способы лечения митохондриальных и метаболических нарушений
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
BR112018011266A2 (pt) ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica?
BR112019005168A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
BR112022000431A2 (pt) Derivados de 2-morfolinopiridina substituídos como inibidores da atr cinase
GEP20227373B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
PE20221443A1 (es) Composiciones y metodos para el tratamiento de infecciones virales
CY1124353T1 (el) C-3 και c-17 τροποποιημενα τριτερπενοειδη ως αναστολεις hiv-1
BR112019005120A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhorar o desempenho de dispersão em aerossol após armazenamento de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
EA201800266A1 (ru) Антивирусная фармацевтическая композиция